Zacks Investment Research upgraded shares of Haemonetics Corporation (HAE) from UNDERPERFORM to NEUTRAL on September 19, 2014, with a target price of $37.00.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Haemonetics Corporation (HAE),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment